More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.31B
EPS
-0.78
P/E ratio
--
Price to sales
1116.98
Dividend yield
--
Beta
2.229692
Previous close
$7.48
Today's open
$7.57
Day's range
$7.34 - $7.79
52 week range
$2.24 - $12.54
show more
CEO
Sean Mcclain
Employees
140
Headquarters
Vancouver, WA
Exchange
Nasdaq Global Select
Shares outstanding
172745810
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Absci Q3 Earnings Call Highlights
Absci NASDAQ: ABSI expects to release interim data from its experimental pattern hair loss treatment in December, followed by a fuller assessment in early 2027, executives said during the company's third-quarter business update on November 12.
MarketBeat • Nov 12, 2026

Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript
Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month
GlobeNewsWire • Nov 12, 2026

Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.
Zacks Investment Research • Nov 12, 2026

Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK
GlobeNewsWire • Nov 12, 2026

Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Seeking Alpha • Nov 11, 2026

Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference (Boston, MA) Fireside chat on Tuesday, November 10th at 1:00 p.m.
GlobeNewsWire • Oct 27, 2026

Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026.
GlobeNewsWire • Oct 13, 2026

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept.
GlobeNewsWire • Sep 24, 2026

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 16, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Absci Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.